Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 7, 2004, Pages 395-400

  Rudovich, N N ^a,b   Leyck Dieken, M G ^c   Rochijtz, H ^a,b   Pfeiffer, A F H ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Novo Nordisk Pharma GmbH   (Germany)

Author keywords

Englycaemic clamp; Hyperglycaemic clamp; Insulin secretion; Insulin sensitivity; Metformin; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; METFORMIN; PLACEBO; REPAGLINIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; AGED; C-PEPTIDE; CARBAMATES; COHORT STUDIES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; PLACEBOS; TIME FACTORS;

EID: 3142719329     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821025     Document Type: Article

References (25)

1. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-C, Avogaro A, Tienego A, Der Parto S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105
2. Chiasson J-L, Hamet P, Verdy M. The effect of Diamicron on the secretion and action of insulin. Diab Res Clin Pract 1991; 14: S47-S52
3. Clark HE and Matthews R. The effect of glimepiride on pancreatic beta-cell function under hyperglycemic clamp and hyperglycemic, euglycemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996; 28: 445-450
4. Dabrowski M, Wahl P, Holmes WE, Ashcroft FM. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001; 44: 747-756
5. De Fronzo RA, Tobin JD, Anders R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (Endocrinol Metab) 1971; 273: E214-E223
6. De Fronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue uptake. Metabolism 1989; 38: 387-395
7. De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. Diabetes Care 1992; 15: 318-356
8. Fuhlenclorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351
9. Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel anti-diabetic agent, administered orally in tablet or solution form intravenously in healthy meal volunteers. Int J Clin Pharmacol Ther 1998; 36: 636-641
10. Haupt A, Kausch C, Dahl D, Bachmann O, Stumvoll M, Haring HU, Matthaei S. Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. Diabetes Care 2002; 25: 2129-2132
11. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33-37
12. Juhl CB, Porksen N, Hollingdal M, Sturis J, Pincus S, Veldhuis JD, Dejgaard A, Schmitz O. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care 2000; 23: 675-681
13. Kahn SE, Montgomery B, Howell WM, Ligueros-Saylan M, Hsu C, Devineni D, McLeod J, Horowitz AD. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes. Diabetes 2000; 49 (Suppl 1): A113
14. + concentrations. Pharmacol Res 1995; 32: 111-114
15. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390
16. Mitrakou A, Kelley D, Mokan M, Veneman T, Reilly J, Gerich J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29
17. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycaemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124
18. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med 1996; 13: S19-S24
19. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000; 23: 518-523
20. Proks P, Reimann F, Green N, Gribble F, Ashcroff F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl 3): S368-376
21. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 31: 550-554
22. Turtle JR. Glucose and insulin secretory response pattern following diet and tolazamide therapy in diabetes. Br Med J 1970; 3: 606-610
23. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794
24. Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diab Med 2000; 17: 225-229
25. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-431